Skip to main content

Coherus Oncology, Inc.

CHRS
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001512762

No open-market purchases or sales by Coherus Oncology, Inc. insiders were filed in the last 90 days; 146 institutions reported holding it in 13F filings for Q2 2026, worth $98.5M in total; no superinvestor holds it.

13F holders, Q1 2021

Institutional positions in Coherus Oncology, Inc. as of Mar 31, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works

Institutional holders
205
No complete 13F data for Q4 2020
Shares held
80.3M
No complete 13F data for Q4 2020
Total value
$1.17B
No complete 13F data for Q4 2020

Holders and value by quarter

Institutions reporting CHRS on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.

Institutional holdersQ1 2021: 205 institutions
Q1 2021: 205 institutionsQ2 2021: 188 institutionsQ3 2021: 188 institutionsQ4 2021: 201 institutionsQ1 2022: 184 institutionsQ2 2022: 176 institutionsQ3 2022: 174 institutionsQ4 2022: 161 institutionsQ1 2023: 163 institutionsQ2 2023: 161 institutionsQ3 2023: 169 institutionsQ4 2023: 156 institutionsQ1 2024: 137 institutionsQ2 2024: 135 institutionsQ3 2024: 128 institutionsQ4 2024: 124 institutionsQ1 2025: 117 institutionsQ2 2025: 112 institutionsQ3 2025: 114 institutionsQ4 2025: 128 institutionsQ1 2026: 158 institutionsQ2 2026: 146 institutions
Value heldQ1 2021: $1.17B
Q1 2021: $1.17BQ2 2021: $1.08BQ3 2021: $1.22BQ4 2021: $1.23BQ1 2022: $980.7MQ2 2022: $572.0MQ3 2022: $743.4MQ4 2022: $622.7MQ1 2023: $536.5MQ2 2023: $371.1MQ3 2023: $347.6MQ4 2023: $271.4MQ1 2024: $197.6MQ2 2024: $142.9MQ3 2024: $79.9MQ4 2024: $90.5MQ1 2025: $50.0MQ2 2025: $40.4MQ3 2025: $84.6MQ4 2025: $81.1MQ1 2026: $120.8MQ2 2026: $98.5M
Institutions holding CHRS and their total value by quarter
QuarterHoldersValue
Q2 2026146$98.5M
Q1 2026158$120.8M
Q4 2025128$81.1M
Q3 2025114$84.6M
Q2 2025112$40.4M
Q1 2025117$50.0M
Q4 2024124$90.5M
Q3 2024128$79.9M
Q2 2024135$142.9M
Q1 2024137$197.6M
Q4 2023156$271.4M
Q3 2023169$347.6M
Q2 2023161$371.1M
Q1 2023163$536.5M
Q4 2022161$622.7M
Q3 2022174$743.4M
Q2 2022176$572.0M
Q1 2022184$980.7M
Q4 2021201$1.23B
Q3 2021188$1.22B
Q2 2021188$1.08B
Q1 2021205$1.17B

Institutions, Q1 2021

Shares, value and share of portfolio for each institution holding Coherus Oncology, Inc..

Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.

Institutions holding CHRS in Q1 2021
InstitutionSharesValue% of portfolioChange in sharesAction
Perceptive Advisors LLC4,697,612$68.6M0.91%––
State Street Corp4,832,381$70.6M0.00%––
JPMorgan Chase & Co5,196,106$75.9M0.01%––
Temasek Holdings (Private) Ltd7,381,116$107.8M0.42%––
BlackRock Inc.11,210,180$163.8M0.00%––